76P - Molecular characterization of PDL1 status of circulating tumor cells (CTCs) isolated with a novel label-free inertial microfluidic system from pati...

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Jen Fraser-Fish
Citation Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363
Authors J. Fraser-Fish1, Z. Ahmad1, R. Kumar2, B. Ebbs1, G. Fowler1, P. Flohr1, M. Crespo1, M. Ahmed2, S. Popat2, J. Bhosle2, U. Banerji3, M. O'Brien2, J.S. de Bono3, T.A. Yap3
  • 1Cancer Biomarkers Laboratory, The Institute of Cancer Research, SM2 5NG - London/GB
  • 2Lung Cancer Unit, Royal Marsden Hospital NHS Foundation Trust, London/GB
  • 3Drug Development Unit, Royal Marsden Hospital And Division Of Clinical Studies, The Institute of Cancer Research, London/GB



The ClearCell® FX system (FX) is a novel label-free inertial microfluidic CTC isolation platform, in contrast to the EpCAM-based CELLSEARCH® system (CS). We hypothesise that label-free CTC capture will lead to more accurate assessment of CTCs, including PD-L1 expression, and capture CTCs that have undergone epithelial-mesenchymal transition, which is prevalent in advanced cancers.


CellTrackerTM labelled EpCAM-high and EpCAM-low cell lines were spiked into healthy volunteer (HV) blood, prior to recovery on FX or CS platforms for initial validation studies. Blood samples were then obtained from pts with advanced non-small cell lung (NSCLC), prostate, ovarian, rectal and breast cancers for CTC isolation on FX and CS. CTCs captured on FX were assessed with 5-color immunofluorescence (IF) (CK, CD45, DAPI, PD-L1, as well as TTF-1 [lung adenocarcinoma], androgen receptor [AR; prostate cancer] or EpCAM [other cancers]). HV blood samples were assessed on FX and CS as controls.


FX and CS captured similar counts in EpCAM-high cell lines (FX 67% ± 11 vs CS 74% ± 10 [p = 0.11]). In contrast, higher cell counts were seen with EpCAM-low cell lines with FX vs CS [62% ± 8 vs 32% ± 9 [p 


Higher CTC counts were isolated with FX vs CS in 86% of pts. CTC PD-L1 heterogeneity was observed and may in part explain differences in antitumor responses to PD-1/PD-L1 inhibitors. Clinical qualification of this 5-color IF PD-L1 CTC assay is ongoing in a PD-1 inhibitor NSCLC trial.

Clinical trial identification

CCR-2472 study opened 2nd August 2004 CCR-3171 study opened 22nd May 2009

Legal entity responsible for the study

The Institute of Cancer Research. The Royal Marsden Hospital


ClearBridge Biomedics


T.A. Yap: Funding for this research project is provided by ClearBridge Biomedics. All other authors have declared no conflicts of interest.